PHARMEXA
More informations about "Pharmexa"
Pharmexa A/S - Hørsholm, Denmark - bionity.com
Mar 5, 2009 Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's …See details»
Pharmexa - Crunchbase Company Profile & Funding
Organization. Pharmexa . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. Vaccine research and development company, based in …See details»
Pharmexa Company Profile 2025: Valuation, Investors ... - PitchBook
Pharmexa’s primary industry is Biotechnology. Is Pharmexa a private or public company? Pharmexa is a Private company. What is Pharmexa’s current revenue? The current revenue …See details»
Pharmexa A/S (CSE: PHARMX) - Life-Sciences-Europe.com
May 29, 2001 Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, rheumatoid arthritis, bone degeneration and …See details»
Pharmexa - Products, Competitors, Financials, Employees, …
About Pharmexa. Developer of of human antibody therapeutics in cancer and other diseases. The company's discovery efforts are carried out by utilizing its integrated antibody library and …See details»
Organization | Pharmexa A/S - Purdue University
Pharmexa A/S Report issue. For profit Phase 1 Phase 3. Founded: Horsholm Denmark ... Organization Overview. First Clinical Trial. 2006 NCT00358566. First Marketed Drug. None …See details»
Pharmexa Limited – UV Guard – Bite Guard – Lice Gone …
Pharmexa is a kiwi owned company and has been around since 1971 and we still play an important part in our country’s economy. Pharmexa is committed to delivering the highest quality, most reliable skin protection products in the …See details»
Pharmexa A/S - Drug pipelines, Patents, Clinical trials - Synapse
Explore Pharmexa A/S with its drug pipeline, therapeutic area, technology platform, 6 clinical trials, and 1 literature, Drug:MVA-BN-HER2, PX-1031(Pharmexa A/S), Tertomotide …See details»
Pharmexa - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Vaccine research and development company, based in Denmark.See details»
Pharmexa Focuses and Adjusts the Organization - GlobeNewswire
Jan 29, 2003 These adjustments also lead to changes in Pharmexa's organization. Pharmexa today announces a lay-off of 31 employees, which together with a number of other changes …See details»
Pharmexa and Affitech to combine operations to create a new …
Mar 5, 2009 The purpose of the merger is to transform Pharmexa from a cancer and infectious disease vaccine business into a company focused on the research and development of human …See details»
Pharmexa-Epimmune Company Profile 2025: Valuation, Investors ...
Pharmexa-Epimmune General Information Description. Developer of cancer vaccines. The company engages in the manufacture of pharmaceuticals used in the treatment of cancer, …See details»
Pharmexa Limited, New Zealand skin care manufacturer …
Pharmexa Limited, New Zealand skin care manufacturer restructures for International Growth Monday, 01 February 2016 15:14 font size decrease font size increase font sizeSee details»
PHARMEXA LIMITED Company Profile - Dun & Bradstreet
Pharmexa limited. d&b business directory home / business directory / retail trade / sporting goods, hobby, musical instrument, book, and miscellaneous retailers / other miscellaneous retailers / …See details»
PX-1031(Pharmexa A/S) - Drug Targets, Indications, Patents
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
Pharmexa-Epimmune, Inc. - Drug pipelines, Patents, Clinical trials ...
Clinical Trials associated with Pharmexa-Epimmune, Inc. NCT00428337 / Completed Phase 1 IIT A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of DNA Vaccine EP-1233 …See details»
Pharmexa Moves GV1001 Into Pivotal Cancer Study
May 3, 2006 Pharmexa A/S received regulatory approvals in four countries for a pivotal Phase III trial of its peptide-based cancer vaccine, GV1001. The first patients will be recruited in the …See details»
MVA-BN-HER2 - Drug Targets, Indications, Patents - Synapse
In July 2022, the World Health Organization (WHO) declared this outbreak a public health emergency of international concern. The objective of this systematic review is to examine the …See details»
PX 1031 - AdisInsight - Springer
Jun 25, 2009 Pharmexa was developing PX 1031, a HER-2/neu-based DNA vaccine for the treatment of cancer, using its AutoVac™ technology. The vaccine, which Pharmexa refers to …See details»